1. Home
  2. MYGN vs GNE Comparison

MYGN vs GNE Comparison

Compare MYGN & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.78

Market Cap

372.1M

Sector

Health Care

ML Signal

HOLD

Logo Genie Energy Ltd. Class B Stock

GNE

Genie Energy Ltd. Class B Stock

HOLD

Current Price

$16.57

Market Cap

408.2M

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYGN
GNE
Founded
1991
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Power Generation
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
372.1M
408.2M
IPO Year
1996
2011

Fundamental Metrics

Financial Performance
Metric
MYGN
GNE
Price
$5.78
$16.57
Analyst Decision
Hold
Analyst Count
9
0
Target Price
★ $4.11
N/A
AVG Volume (30 Days)
★ 2.7M
54.3K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
★ 1.78%
EPS Growth
N/A
★ 95.65
EPS
N/A
★ 0.54
Revenue
★ $771,400,000.00
$425,202,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.47
$1.86
P/E Ratio
★ N/A
$31.07
Revenue Growth
★ 2.33
N/A
52 Week Low
$2.74
$12.69
52 Week High
$8.50
$17.11

Technical Indicators

Market Signals
Indicator
MYGN
GNE
Relative Strength Index (RSI) 73.82 56.80
Support Level $5.57 $13.46
Resistance Level $6.34 $17.11
Average True Range (ATR) 0.33 0.45
MACD 0.16 -0.05
Stochastic Oscillator 90.50 64.44

Price Performance

Historical Comparison
MYGN
GNE

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

About GNE Genie Energy Ltd. Class B Stock

Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.

Share on Social Networks: